JPWO2019229701A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019229701A5
JPWO2019229701A5 JP2020566220A JP2020566220A JPWO2019229701A5 JP WO2019229701 A5 JPWO2019229701 A5 JP WO2019229701A5 JP 2020566220 A JP2020566220 A JP 2020566220A JP 2020566220 A JP2020566220 A JP 2020566220A JP WO2019229701 A5 JPWO2019229701 A5 JP WO2019229701A5
Authority
JP
Japan
Prior art keywords
bcma
cdr
binding molecule
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566220A
Other languages
Japanese (ja)
Other versions
JP2021525715A (en
JP7398396B2 (en
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054500 external-priority patent/WO2019229701A2/en
Publication of JP2021525715A publication Critical patent/JP2021525715A/en
Publication of JPWO2019229701A5 publication Critical patent/JPWO2019229701A5/ja
Priority to JP2023138838A priority Critical patent/JP2023166470A/en
Application granted granted Critical
Publication of JP7398396B2 publication Critical patent/JP7398396B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

ＫＭＳ１１異種移植片モデルにおいて、いくつかの予備データは、２価ＡＢ３及びｈ２Ｂ４＿Ｃ２９が、ＥｎｇＭａｂ及びＪａｎｓｓｅｎ製のＢＣＭＡ－ＣＤ３二重特異性分子と比較してより高い抗腫瘍活性を有することを示唆している（データは示さず）。

以下の態様が包含され得る。
［１］ ヒトＢＣＭＡに特異的に結合し、且つ表１Ａ－１、表１Ｂ－１、表１Ｃ－１、表１Ｄ－１、表１Ｅ－１、表１Ｆ－１、表１Ｇ－１、表１Ｈ－１、表１Ｉ－１、表１Ｊ－１、表１Ｋ－１（ａ）、表１Ｋ－１（ｂ）、表１Ｌ－１、表１Ｍ－１、表１Ｎ－１（ａ）又は表１Ｎ－１（ｂ）に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ａ－２、表１Ｂ－２、表１Ｃ－２、表１Ｄ－２、表１Ｅ－２、表１Ｆ－２、表１Ｇ－２、表１Ｈ－２、表１Ｉ－２、表１Ｊ－２、表１Ｋ－２、表１Ｋ－２、表１Ｌ－２、表１Ｍ－２、表１Ｎ－２又は表１Ｎ－２にそれぞれ記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含むＢＣＭＡ結合分子。
［２］ 表１Ａ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ａ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［３］ 表１Ｂ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｂ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［４］ 表１Ｃ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｃ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［５］ 表１Ｄ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｄ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［６］ 表１Ｅ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｅ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［７］ 表１Ｆ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｆ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［８］ 表１Ｇ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｇ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［９］ 表１Ｈ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｈ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［１０］ 表１Ｉ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｉ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［１１］ 表１Ｊ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｊ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［１２］ 表１Ｋ－１（ａ）又は表１Ｋ－１（ｂ）に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｋ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［１３］ 表１Ｌ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｌ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［１４］ 表１Ｍ－１に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｍ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［１５］ 表１Ｎ－１（ａ）又は表１Ｎ－１（ｂ）に記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに表１Ｎ－２に記載される対応するＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［１６］ 前記ＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２、ＣＤＲ－Ｌ３、ＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列は、ＡＢ１のものである、上記［４］～［９］のいずれか一項に記載のＢＣＭＡ結合分子。
［１７］ 前記ＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２、ＣＤＲ－Ｌ３、ＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列は、ＡＢ２のものである、上記［４］～［９］のいずれか一項に記載のＢＣＭＡ結合分子。
［１８］ 前記ＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２、ＣＤＲ－Ｌ３、ＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列は、ＡＢ３のものである、上記［１０］～［１５］のいずれか一項に記載のＢＣＭＡ結合分子。
［１９］ 表１Ｏ－１に記載される軽鎖可変配列及び表１Ｏ－２に記載される対応する重鎖可変配列を含む、上記［１］に記載のＢＣＭＡ結合分子。
［２０］ 前記軽鎖可変配列及び前記対応する重鎖可変配列は、ＡＢ１のものである、上記［１９］に記載のＢＣＭＡ結合分子。
［２１］ 前記軽鎖可変配列及び前記対応する重鎖可変配列は、ＡＢ２のものである、上記［１９］に記載のＢＣＭＡ結合分子。
［２２］ 前記軽鎖可変配列及び前記対応する重鎖可変配列は、ＡＢ３のものである、上記［１９］に記載のＢＣＭＡ結合分子。
［２３］ 抗体、抗体フラグメント、ｓｃＦｖ、ｄｓＦｖ、Ｆｖ、Ｆａｂ、ｓｃＦａｂ、（Ｆａｂ’）２又は単一ドメイン抗体（ＳＤＡＢ）を含む、上記［１］～［２２］のいずれか一項に記載のＢＣＭＡ結合分子。
［２４］ 抗体又は抗体フラグメントを含む、上記［２３］に記載のＢＣＭＡ結合分子。
［２５］ ｓｃＦｖを含む、上記［２３］に記載のＢＣＭＡ結合分子。
［２６］ 多重特異性結合分子である、上記［１］～［２５］のいずれか一項に記載のＢＣＭＡ結合分子。
［２７］ 二重特異性結合分子（ＢＢＭ）である、上記［２６］に記載のＢＣＭＡ結合分子。
［２８］ 前記ＢＢＭは、
（ａ）ＢＣＭＡに特異的に結合する抗原結合ドメイン１（ＡＢＤ１）；及び
（ｂ）ヒトＴ細胞受容体（ＴＣＲ）複合体の構成要素に特異的に結合する抗原結合ドメイン２（ＡＢＤ２）
を含む、上記［２７］に記載のＢＣＭＡ結合分子。
［２９］ ＡＢＤ１は、ＡＢＤ２がヒトＴＣＲ複合体の構成要素に結合されるのと同時にＢＣＭＡに結合することが可能である、上記［２８］に記載のＢＣＭＡ結合分子。
［３０］ ＡＢＤ１は、抗体、抗体フラグメント、ｓｃＦｖ、ｄｓＦｖ、Ｆｖ、Ｆａｂ、ｓｃＦａｂ、（Ｆａｂ’）２、単一ドメイン抗体（ＳＤＡＢ）、ＶＨ若しくはＶＬドメイン又はラクダ科ＶＨＨドメインである、上記［２８］又は［２９］に記載のＢＣＭＡ結合分子。
［３１］ ＡＢＤ１は、ｓｃＦｖである、上記［３０］に記載のＢＣＭＡ結合分子。
［３２］ ＡＢＤ１は、Ｆａｂである、上記［３０］に記載のＢＣＭＡ結合分子。
［３３］ ＡＢＤ１は、抗ＢＣＭＡ抗体又はその抗原結合ドメインである、上記［３０］に記載のＢＣＭＡ結合分子。
［３４］ ＡＢＤ２は、抗体、抗体フラグメント、ｓｃＦｖ、ｄｓＦｖ、Ｆｖ、Ｆａｂ、ｓｃＦａｂ、（Ｆａｂ’）２、単一ドメイン抗体（ＳＤＡＢ）、ＶＨ若しくはＶＬドメイン又はラクダ科ＶＨＨドメインである、上記［２８］～［３３］のいずれか一項に記載のＢＣＭＡ結合分子。
［３５］ ＡＢＤ２は、ｓｃＦｖである、上記［３４］に記載のＢＣＭＡ結合分子。
［３６］ ＡＢＤ２は、Ｆａｂである、上記［３４］に記載のＢＣＭＡ結合分子。
［３７］ 前記ＴＣＲ複合体の前記構成要素は、ＣＤ３である、上記［２８］～［３６］のいずれか一項に記載のＢＣＭＡ結合分子。
［３８］ ＡＢＤ２は、抗ＣＤ３抗体又はその抗原結合ドメインである、上記［３７］に記載のＢＣＭＡ結合分子。
［３９］ ＡＢＤ２は、ＣＤ３－１～ＣＤ３－１２７のいずれか１つのＣＤＲ配列を含む、上記［３８］に記載のＢＣＭＡ結合分子。
［４０］ ２価である、上記［２７］～［３９］のいずれか一項に記載のＢＣＭＡ結合分子。
［４１］ ３価である、上記［２７］～［３９］のいずれか一項に記載のＢＣＭＡ結合分子。
［４２］ ４価である、上記［２７］～［３９］のいずれか一項に記載のＢＣＭＡ結合分子。
［４３］ （ａ）第１のポリペプチドであって、
（ｉ）第１のＦｃ領域を含む第１の重鎖定常ドメイン；
（ｉｉ）表３Ａ中のＣＤ３－２３として示されるｓｃＦｖのアミノ酸配列を含むｓｃＦｖであって、ヒンジによって前記第１のＦｃ領域のＮ末端に共有結合されるｓｃＦｖ
を含む第１のポリペプチド；
（ｂ）第２のポリペプチドであって、
（ｉ）重鎖可変ドメイン；
（ｉｉ）第２のＦｃ領域を含む第２の重鎖定常ドメイン
を含む第２のポリペプチド；及び
（ｃ）軽鎖定常ドメイン及び軽鎖可変ドメインを含む第３のポリペプチド
を含むＢＣＭＡ結合分子であって、
Ａ．前記第１及び第２のＦｃ領域は、Ｆｃドメインを形成し；
Ｂ．前記第１及び第２のＦｃ領域は、Ｓ３６４Ｋ／Ｅ３５７Ｑ：Ｌ３６８Ｄ／３７０Ｓを含むアミノ酸置換の組を有し；
Ｃ．前記第１及び／又は第２のＦｃ領域は、アミノ酸修飾Ｅ２２３Ｐ、Ｌ２３４Ｖ、Ｌ２３５Ａ、Ｇ２３６ｄｅｌ及びＳ２６７Ｋを含み；
Ｄ．前記第１及び／又は第２のＦｃ領域は、アミノ酸置換Ｎ２０８Ｄ、Ｑ２９５Ｅ、Ｎ３８４Ｄ、Ｑ４１８Ｅ及びＮ４２１Ｄを含み；及び
Ｅ．前記軽鎖可変ドメイン及び前記重鎖可変ドメインは、表１Ｏ－１及び表１Ｏ－２に記載されるＡＢ１、ＡＢ２又はＡＢ３の軽鎖可変ドメイン及び重鎖可変ドメイン配列を含む、ＢＣＭＡ結合分子。
［４４］ （ａ）第１のポリペプチドであって、そのアミノ酸配列は、配列番号５０９のアミノ酸配列を含む、第１のポリペプチド；
（ｂ）第２のポリペプチドであって、そのアミノ酸配列は、配列番号５１０のアミノ酸配列を含む、第２のポリペプチド；及び
（ｃ）第３のポリペプチドであって、そのアミノ酸配列は、配列番号５０４のアミノ酸配列を含む、第３のポリペプチド
を含むＢＣＭＡ結合分子。
［４５］ 薬剤として使用するための、上記［１］～［４４］のいずれか一項に記載のＢＣＭＡ結合分子。
［４６］ ＢＣＭＡの発現に関連する疾患又は障害を治療するのに使用するための、上記［１］～［４４］のいずれか一項に記載のＢＣＭＡ結合分子。
［４７］ 上記［１］～［４４］のいずれか一項に記載のＢＣＭＡ結合分子及び薬剤を含むコンジュゲート。
［４８］ 上記［１］～［４４］のいずれか一項に記載のＢＣＭＡ結合分子又は上記［４７］に記載のコンジュゲート及び薬学的に許容される賦形剤を含む医薬組成物。
［４９］ ＢＣＭＡの発現に関連する疾患又は障害に罹患した対象を治療する方法であって、有効量の、上記［１］～［４４］のいずれか一項に記載のＢＣＭＡ結合分子、上記［４７］に記載のコンジュゲート又は上記［４８］に記載の医薬組成物を前記対象に投与することを含む方法。
［５０］ 前記疾患又は障害は、形質細胞腫を含む、上記［４９］に記載の方法。
［５１］ 前記疾患又は障害は、細胞表面ＢＣＭＡを発現するＢ細胞悪性腫瘍を含む、上記［４９］に記載の方法。
［５２］ 少なくとも１つの追加的な薬剤を前記対象に投与することをさらに含む、上記［４９］～［５１］のいずれか一項に記載の方法。
［５３］ 前記疾患又は障害は、自己免疫疾患を含む、上記［４９］に記載の方法。
［５４］ 上記［１］～［４４］のいずれか一項に記載のＢＣＭ結合分子をコードする１つ又は複数の核酸。
［５５］ 上記［１］～［４４］のいずれか一項に記載のＢＣＭＡ結合分子を発現するように操作された細胞。
［５６］ １つ以上のプロモーターの制御下において、上記［１］～［４４］のいずれか一項に記載のＢＣＭＡ結合分子又は上記［４７］に記載のコンジュゲートをコードする１つ以上の核酸配列を含む１つ以上の発現ベクターでトランスフェクトされた細胞。
［５７］ ＢＣＭＡ結合分子を産生する方法であって、
（ａ）前記ＢＣＭＡ結合分子が発現される条件において、上記［５５］又は［５６］に記載の細胞を培養することと；
（ｂ）細胞培養物から前記ＢＣＭＡ結合分子を回収することと
を含む方法。
In the KMS11 xenograft model, some preliminary data suggest that divalent AB3 and h2B4_C29 have higher antitumor activity compared to BCMA-CD3 bispecific molecules from EngMab and Janssen. Yes (data not shown).

The following aspects may be included.
[1] It specifically binds to human BCMA and is Table 1A-1, Table 1B-1, Table 1C-1, Table 1D-1, Table 1E-1, Table 1F-1, Table 1G-1, Table 1H. -1, Table 1I-1, Table 1J-1, Table 1K-1 (a), Table 1K-1 (b), Table 1L-1, Table 1M-1, Table 1N-1 (a) or Table 1N- The CDR-L1, CDR-L2 and CDR-L3 sequences described in 1 (b) and Table 1A-2, Table 1B-2, Table 1C-2, Table 1D-2, Table 1E-2, Table 1F-2. , Table 1G-2, Table 1H-2, Table 1I-2, Table 1J-2, Table 1K-2, Table 1K-2, Table 1L-2, Table 1M-2, Table 1N-2 or Table 1N-2. BCMA binding molecule comprising the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences described in.
[2] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1A-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1A-2. The BCMA-binding molecule according to [1].
[3] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1B-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1B-2. The BCMA-binding molecule according to [1].
[4] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1C-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1C-2. The BCMA-binding molecule according to [1].
[5] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1D-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1D-2. The BCMA-binding molecule according to [1].
[6] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1E-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1E-2. The BCMA-binding molecule according to [1].
[7] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1F-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1F-2. The BCMA-binding molecule according to [1].
[8] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1G-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1G-2. The BCMA-binding molecule according to [1].
[9] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1H-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1H-2. The BCMA-binding molecule according to [1].
[10] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1I-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1I-2. The BCMA-binding molecule according to [1].
[11] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1J-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1J-2. The BCMA-binding molecule according to [1].
[12] CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1K-1 (a) or Table 1K-1 (b) and the corresponding CDR-H1, CDRs listed in Table 1K-2. -The BCMA binding molecule according to [1] above, which comprises the H2 and CDR-H3 sequences.
[13] The above, including the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1L-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1L-2. The BCMA-binding molecule according to [1].
[14] The above, comprising the CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1M-1 and the corresponding CDR-H1, CDR-H2 and CDR-H3 sequences listed in Table 1M-2. The BCMA-binding molecule according to [1].
[15] The CDR-L1, CDR-L2 and CDR-L3 sequences listed in Table 1N-1 (a) or Table 1N-1 (b) and the corresponding CDR-H1, CDRs listed in Table 1N-2. -The BCMA binding molecule according to [1] above, which comprises the H2 and CDR-H3 sequences.
[16] The CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences are those of AB1, in any one of the above [4] to [9]. The BCMA binding molecule described.
[17] The CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences are those of AB2, according to any one of the above [4] to [9]. The BCMA binding molecule described.
[18] The CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences are those of AB3, in any one of the above [10] to [15]. The BCMA binding molecule described.
[19] The BCMA binding molecule according to [1] above, which comprises the light chain variable sequence shown in Table 1O-1 and the corresponding heavy chain variable sequence shown in Table 1O-2.
[20] The BCMA binding molecule according to [19] above, wherein the light chain variable sequence and the corresponding heavy chain variable sequence are those of AB1.
[21] The BCMA binding molecule according to [19] above, wherein the light chain variable sequence and the corresponding heavy chain variable sequence are those of AB2.
[22] The BCMA binding molecule according to [19] above, wherein the light chain variable sequence and the corresponding heavy chain variable sequence are those of AB3.
[23] The item according to any one of the above [1] to [22], which comprises an antibody, an antibody fragment, scFv, dsFv, Fv, Fab, scFab, (Fab') 2 or a single domain antibody (SDAB). BCMA binding molecule.
[24] The BCMA binding molecule according to [23] above, which comprises an antibody or antibody fragment.
[25] The BCMA-binding molecule according to [23] above, which comprises scFv.
[26] The BCMA-binding molecule according to any one of the above [1] to [25], which is a multispecific binding molecule.
[27] The BCMA-binding molecule according to the above [26], which is a bispecific binding molecule (BBM).
[28] The BBM is
(A) Antigen-binding domain 1 (ABD1) that specifically binds to BCMA; and
(B) Antigen-binding domain 2 (ABD2) that specifically binds to a component of the human T cell receptor (TCR) complex.
The BCMA binding molecule according to [27] above.
[29] The BCMA-binding molecule according to [28] above, wherein ABD1 is capable of binding to BCMA at the same time that ABD2 is bound to a component of the human TCR complex.
[30] ABD1 is an antibody, antibody fragment, scFv, dsFv, Fv, Fab, scFab, (Fab') 2, single domain antibody (SDAB), VH or VL domain or Camelid VHH domain, as described above [28]. ] Or the BCMA-binding molecule according to [29].
[31] The BCMA-binding molecule according to the above [30], wherein ABD1 is scFv.
[32] The BCMA-binding molecule according to the above [30], wherein ABD1 is Fab.
[33] The BCMA-binding molecule according to the above [30], wherein ABD1 is an anti-BCMA antibody or an antigen-binding domain thereof.
[34] ABD2 is an antibody, antibody fragment, scFv, dsFv, Fv, Fab, scFab, (Fab') 2, single domain antibody (SDAB), VH or VL domain or Camelid VHH domain, as described above [28]. ] To [33], the BCMA binding molecule according to any one of the following items.
[35] The BCMA-binding molecule according to [34] above, wherein ABD2 is scFv.
[36] The BCMA-binding molecule according to the above [34], wherein ABD2 is Fab.
[37] The BCMA-binding molecule according to any one of [28] to [36] above, wherein the component of the TCR complex is CD3.
[38] The BCMA-binding molecule according to the above [37], wherein ABD2 is an anti-CD3 antibody or an antigen-binding domain thereof.
[39] The BCMA-binding molecule according to [38] above, wherein ABD2 comprises the CDR sequence of any one of CD3-1 to CD3-127.
[40] The BCMA-binding molecule according to any one of the above [27] to [39], which is divalent.
[41] The BCMA-binding molecule according to any one of the above [27] to [39], which is trivalent.
[42] The BCMA-binding molecule according to any one of the above [27] to [39], which is tetravalent.
[43] (a) The first polypeptide, which is
(I) A first heavy chain constant domain containing a first Fc region;
(Ii) A scFv containing the amino acid sequence of scFv shown as CD3-23 in Table 3A, which is covalently attached to the N-terminus of the first Fc region by a hinge.
First polypeptide containing;
(B) A second polypeptide,
(I) Heavy chain variable domain;
(Ii) A second heavy chain constant domain containing a second Fc region
A second polypeptide containing; and
(C) A third polypeptide containing a light chain constant domain and a light chain variable domain
BCMA-binding molecule containing
A. The first and second Fc regions form an Fc domain;
B. The first and second Fc regions have a set of amino acid substitutions comprising S364K / E357Q: L368D / 370S;
C. The first and / or second Fc region comprises amino acid modifications E223P, L234V, L235A, G236del and S267K;
D. The first and / or second Fc region comprises amino acid substitutions N208D, Q295E, N384D, Q418E and N421D; and
E. The light chain variable domain and the heavy chain variable domain are BCMA binding molecules comprising the light chain variable domain and heavy chain variable domain sequence of AB1, AB2 or AB3 shown in Tables 1O-1 and 1O-2.
[44] (a) The first polypeptide, wherein the amino acid sequence comprises the amino acid sequence of SEQ ID NO: 509;
(B) A second polypeptide, wherein the amino acid sequence comprises the amino acid sequence of SEQ ID NO: 510; and
(C) A third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 504.
BCMA binding molecule containing.
[45] The BCMA-binding molecule according to any one of the above [1] to [44] for use as a drug.
[46] The BCMA-binding molecule according to any one of the above [1] to [44], which is used for treating a disease or disorder related to the expression of BCMA.
[47] A conjugate containing the BCMA-binding molecule and the drug according to any one of the above [1] to [44].
[48] A pharmaceutical composition comprising the BCMA-binding molecule according to any one of the above [1] to [44] or the conjugate according to the above [47] and a pharmaceutically acceptable excipient.
[49] A method for treating a subject suffering from a disease or disorder related to the expression of BCMA, wherein an effective amount of the BCMA binding molecule according to any one of the above [1] to [44], the above [ 47] A method comprising administering to the subject the conjugate according to [48] or the pharmaceutical composition according to the above [48].
[50] The method of [49] above, wherein the disease or disorder comprises plasmacytoma.
[51] The method according to [49] above, wherein the disease or disorder comprises a B cell malignant tumor expressing cell surface BCMA.
[52] The method according to any one of [49] to [51] above, further comprising administering to the subject at least one additional agent.
[53] The method according to [49] above, wherein the disease or disorder comprises an autoimmune disease.
[54] One or more nucleic acids encoding the BCM-binding molecule according to any one of the above [1] to [44].
[55] A cell engineered to express the BCMA-binding molecule according to any one of the above [1] to [44].
[56] Under the control of one or more promoters, the BCMA-binding molecule according to any one of [1] to [44] above or one or more nucleic acids encoding the conjugate according to [47] above. Cells transfected with one or more expression vectors containing a sequence.
[57] A method for producing a BCMA-binding molecule.
(A) Culturing the cells according to the above [55] or [56] under the condition that the BCMA binding molecule is expressed;
(B) To recover the BCMA-binding molecule from the cell culture.
How to include.

Claims (20)

ヒトＢＣＭＡに特異的に結合し、且つ
（ａ）Ｋａｂａｔ及びＣｈｏｔｈｉａの定義の組み合わせによる、配列番号２６、１０２及び１１０にそれぞれ記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに配列番号１８８、１１２及び４９にそれぞれ記載されるＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列、
（ｂ）Ｋａｂａｔの定義による、配列番号２６、１０２及び１１０にそれぞれ記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに配列番号３９、１１２及び４９にそれぞれ記載されるＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列、
（ｃ）Ｃｈｏｔｈｉａの定義による、配列番号２７、３１及び１３６にそれぞれ記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに配列番号１３８、１４０及び４９にそれぞれ記載されるＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列、又は
（ｄ）ＩＭＧＴの定義による、配列番号２８、１５４及び１１０にそれぞれ記載されるＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２及びＣＤＲ－Ｌ３配列並びに配列番号１６２、１６５及び５１にそれぞれ記載されるＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２及びＣＤＲ－Ｈ３配列
を含むＢＣＭＡ結合分子。 It specifically binds to human BCMA and
(A) CDR-L1, CDR-L2 and CDR-L3 sequences set forth in SEQ ID NOs: 26, 102 and 110, respectively, and CDRs set forth in SEQ ID NOs: 188, 112 and 49, respectively, according to a combination of Kabat and Chothia definitions. -H1, CDR-H2 and CDR-H3 sequences,
(B) CDR-L1, CDR-L2 and CDR-L3 sequences set forth in SEQ ID NOs: 26, 102 and 110, respectively, and CDR-H1, CDRs set forth in SEQ ID NOs: 39, 112 and 49, respectively, as defined by Kabat. -H2 and CDR-H3 sequences,
(C) CDR-L1, CDR-L2 and CDR-L3 sequences set forth in SEQ ID NOs: 27, 31 and 136, respectively, and CDR-H1, CDRs set forth in SEQ ID NOs: 138, 140 and 49, respectively, as defined by Chothia. -H2 and CDR-H3 sequences, or
(D) CDR-L1, CDR-L2 and CDR-L3 sequences set forth in SEQ ID NOs: 28, 154 and 110, respectively, and CDR-H1, CDRs set forth in SEQ ID NOs: 162, 165 and 51, respectively, as defined by IMGT. -H2 and CDR-H3 sequences
BCMA binding molecule containing. 配列番号２００のアミノ酸配列を含む軽鎖可変配列及び配列番号２２４のアミノ酸配列を含む重鎖可変配列を含む、請求項１に記載のＢＣＭＡ結合分子。 The BCMA binding molecule of claim 1, comprising a light chain variable sequence comprising the amino acid sequence of SEQ ID NO: 200 and a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 224 . 抗体、抗体フラグメント、ｓｃＦｖ、ｄｓＦｖ、Ｆｖ、Ｆａｂ、ｓｃＦａｂ、（Ｆａｂ’）２又は単一ドメイン抗体（ＳＤＡＢ）を含む、請求項１又は請求項２に記載のＢＣＭＡ結合分子。 The BCMA binding molecule of claim 1 or 2 , comprising an antibody, antibody fragment, scFv, dsFv, Fv, Fab, scFab, (Fab') 2 or a single domain antibody (SDAB). 多重特異性結合分子である、請求項１～３のいずれか一項に記載のＢＣＭＡ結合分子。 The BCMA-binding molecule according to any one of claims 1 to 3 , which is a multispecific binding molecule. 二重特異性結合分子（ＢＢＭ）である、請求項４に記載のＢＣＭＡ結合分子。 The BCMA binding molecule according to claim 4 , which is a bispecific binding molecule (BBM). 前記ＢＢＭは、
（ａ）ＢＣＭＡに特異的に結合する抗原結合ドメイン１（ＡＢＤ１）；及び
（ｂ）ヒトＴ細胞受容体（ＴＣＲ）複合体の構成要素に特異的に結合する抗原結合ドメイン２（ＡＢＤ２）
を含む、請求項５に記載のＢＣＭＡ結合分子。 The BBM is
(A) Antigen-binding domain 1 (ABD1) that specifically binds to BCMA; and (b) Antigen-binding domain 2 (ABD2) that specifically binds to components of the human T cell receptor (TCR) complex.
The BCMA binding molecule according to claim 5 . ＡＢＤ１は、ＡＢＤ２がヒトＴＣＲ複合体の構成要素に結合されるのと同時にＢＣＭＡに結合することが可能である、請求項６に記載のＢＣＭＡ結合分子。 The BCMA-binding molecule according to claim 6 , wherein ABD1 is capable of binding to BCMA at the same time that ABD2 is bound to a component of the human TCR complex. ＡＢＤ１又はＡＢＤ２は、抗体、抗体フラグメント、ｓｃＦｖ、ｄｓＦｖ、Ｆｖ、Ｆａｂ、ｓｃＦａｂ、（Ｆａｂ’）２、単一ドメイン抗体（ＳＤＡＢ）、ＶＨ若しくはＶＬドメイン又はラクダ科ＶＨＨドメインである、請求項６又は請求項７に記載のＢＣＭＡ結合分子。 ABD1 or ABD2 is an antibody, antibody fragment, scFv, dsFv, Fv, Fab, scFab, (Fab') 2, single domain antibody (SDAB), VH or VL domain or Camelid VHH domain, claim 6 or The BCMA binding molecule according to claim 7 . 前記ＴＣＲ複合体の前記構成要素は、ＣＤ３であり、任意選択で、ＡＢＤ２は、抗ＣＤ３抗体又はその抗原結合ドメインであり、任意選択で、ＡＢＤ２は、ＣＤ３－１～ＣＤ３－１２７のいずれか１つのＣＤＲ配列を含む、請求項６～８のいずれか一項に記載のＢＣＭＡ結合分子。 The component of the TCR complex is CD3 , optionally ABD2 is an anti-CD3 antibody or antigen binding domain thereof, and optionally, ABD2 is any of CD3-1 to CD3-127. The BCMA binding molecule according to any one of claims 6 to 8 , which comprises one CDR sequence . ２価、３価、又は４価である、請求項５～９のいずれか一項に記載のＢＣＭＡ結合分子。 The BCMA-binding molecule according to any one of claims 5 to 9 , which is divalent, trivalent, or tetravalent . 請求項１に記載のＢＣＭＡ結合分子であって、
（ａ）第１のポリペプチドであって、
（ｉ）第１のＦｃ領域を含む第１の重鎖定常ドメイン；
（ｉｉ）配列番号２９４のアミノ酸配列を含むｓｃＦｖであって、ヒンジによって前記第１のＦｃ領域のＮ末端に共有結合されるｓｃＦｖ
を含む第１のポリペプチド；
（ｂ）第２のポリペプチドであって、
（ｉ）重鎖可変ドメイン；
（ｉｉ）第２のＦｃ領域を含む第２の重鎖定常ドメイン
を含む第２のポリペプチド；及び
（ｃ）軽鎖定常ドメイン及び軽鎖可変ドメインを含む第３のポリペプチド
を含み、ここで、
Ａ．前記第１及び第２のＦｃ領域は、Ｆｃドメインを形成し；
Ｂ．前記第１及び第２のＦｃ領域は、Ｓ３６４Ｋ／Ｅ３５７Ｑ：Ｌ３６８Ｄ／３７０Ｓを含むアミノ酸置換の組を有し；
Ｃ．前記第１及び／又は第２のＦｃ領域は、アミノ酸修飾Ｅ２２３Ｐ、Ｌ２３４Ｖ、Ｌ２３５Ａ、Ｇ２３６ｄｅｌ及びＳ２６７Ｋを含み；
Ｄ．前記第１及び／又は第２のＦｃ領域は、アミノ酸置換Ｎ２０８Ｄ、Ｑ２９５Ｅ、Ｎ３８４Ｄ、Ｑ４１８Ｅ及びＮ４２１Ｄを含み；及び
Ｅ．前記軽鎖可変ドメイン及び前記重鎖可変ドメインは、配列番号２００および配列番号２２４の軽鎖可変ドメイン及び重鎖可変ドメイン配列をそれぞれ含む、ＢＣＭＡ結合分子。 The BCMA-binding molecule according to claim 1.
(A) The first polypeptide, which is
(I) A first heavy chain constant domain containing a first Fc region;
(Ii) A scFv containing the amino acid sequence of SEQ ID NO: 294 , which is covalently attached to the N-terminus of the first Fc region by a hinge.
First polypeptide containing;
(B) A second polypeptide,
(I) Heavy chain variable domain;
(Ii) a second polypeptide comprising a second heavy chain constant domain comprising a second Fc region; and (c) a third polypeptide comprising a light chain constant domain and a light chain variable domain . and,
A. The first and second Fc regions form an Fc domain;
B. The first and second Fc regions have a set of amino acid substitutions comprising S364K / E357Q: L368D / 370S;
C. The first and / or second Fc region comprises amino acid modifications E223P, L234V, L235A, G236del and S267K;
D. The first and / or second Fc region comprises amino acid substitutions N208D, Q295E, N384D, Q418E and N421D; and E.I. The light chain variable domain and the heavy chain variable domain are BCMA binding molecules comprising the light chain variable domain and heavy chain variable domain sequences of SEQ ID NO: 200 and SEQ ID NO: 224 , respectively . 請求項１に記載のＢＣＭＡ結合分子であって、 （ａ）第１のポリペプチドであって、そのアミノ酸配列は、配列番号５０９のアミノ酸配列を含む、第１のポリペプチド；
（ｂ）第２のポリペプチドであって、そのアミノ酸配列は、配列番号５１０のアミノ酸配列を含む、第２のポリペプチド；及び
（ｃ）第３のポリペプチドであって、そのアミノ酸配列は、配列番号５０４のアミノ酸配列を含む、第３のポリペプチド
を含むＢＣＭＡ結合分子。 The BCMA binding molecule according to claim 1, (a) the first polypeptide, wherein the amino acid sequence comprises the amino acid sequence of SEQ ID NO: 509;
(B) A second polypeptide having an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 510; and (c) a third polypeptide having an amino acid sequence thereof. BCMA binding molecule comprising a third polypeptide comprising the amino acid sequence of SEQ ID NO: 504. 薬剤として使用するための、請求項１～１２のいずれか一項に記載のＢＣＭＡ結合分子。 The BCMA-binding molecule according to any one of claims 1 to 12 , which is used as a drug. ＢＣＭＡの発現に関連する疾患又は障害を治療するのに使用するための、請求項１～１３のいずれか一項に記載のＢＣＭＡ結合分子。 The BCMA-binding molecule according to any one of claims 1 to 13 , for use in treating a disease or disorder associated with the expression of BCMA. 請求項１～１４のいずれか一項に記載のＢＣＭＡ結合分子及び薬剤を含むコンジュゲート。 A conjugate comprising the BCMA binding molecule and the agent according to any one of claims 1 to 14 . 請求項１～１５のいずれか一項に記載のＢＣＭＡ結合分子又はコンジュゲート及び薬学的に許容される賦形剤を含む医薬組成物。 A pharmaceutical composition comprising the BCMA-binding molecule or conjugate according to any one of claims 1 to 15 and a pharmaceutically acceptable excipient. ＢＣＭＡの発現に関連する疾患又は障害に罹患した対象を治療する方法で用いるための、請求項１～１６のいずれか一項に記載のＢＣＭＡ結合分子、コンジュゲート又は医薬組成物であって、任意選択で、前記方法は、少なくとも１つの追加的な薬剤を前記対象に投与することをさらに含み、任意選択で、
（ａ）前記疾患又は障害は、形質細胞腫を含む、
（ｂ）前記疾患又は障害は、細胞表面ＢＣＭＡを発現するＢ細胞悪性腫瘍を含み、任意選択で、前記Ｂ細胞悪性腫瘍は、多発性骨髄腫である、又は
（ｃ）前記疾患又は障害は、自己免疫疾患を含む、
ＢＣＭＡ結合分子、コンジュゲート又は医薬組成物。 The BCMA-binding molecule, conjugate or pharmaceutical composition according to any one of claims 1 to 16, which is optionally used in a method for treating a subject suffering from a disease or disorder related to the expression of BCMA. Optionally, the method further comprises administering at least one additional agent to the subject, optionally.
(A) The disease or disorder comprises plasmacytoma.
(B) The disease or disorder comprises a B cell malignant tumor expressing cell surface BCMA, optionally said the B cell malignant tumor is multiple myeloma or.
(C) The disease or disorder includes an autoimmune disease.
BCMA binding molecule, conjugate or pharmaceutical composition . 請求項１～１４のいずれか一項に記載のＢＣＭＡ結合分子をコードする１つ又は複数の核酸。 One or more nucleic acids encoding the BCM A -binding molecule according to any one of claims 1-14 . 請求項１～１４のいずれか一項に記載のＢＣＭＡ結合分子を発現するように操作された、又は１つ以上のプロモーターの制御下において、請求項１～１５のいずれか一項に記載のＢＣＭＡ結合分子又はコンジュゲートをコードする１つ以上の核酸配列を含む１つ以上の発現ベクターでトランスフェクトされた、細胞。 The BCMA according to any one of claims 1 to 15, which has been engineered to express the BCMA binding molecule according to any one of claims 1 to 14 , or under the control of one or more promoters. Cells transfected with one or more expression vectors containing one or more nucleic acid sequences encoding a binding molecule or conjugate . ＢＣＭＡ結合分子を産生する方法であって、
（ａ）前記ＢＣＭＡ結合分子が発現される条件において、請求項１９に記載の細胞を培養することと；
（ｂ）細胞培養物から前記ＢＣＭＡ結合分子を回収することと
を含む方法。
A method for producing BCMA-binding molecules.
(A) Culturing the cell according to claim 19 under the condition that the BCMA binding molecule is expressed;
(B) A method comprising recovering the BCMA binding molecule from a cell culture.
JP2020566220A 2018-06-01 2019-05-30 Binding molecules for BCMA and their uses Active JP7398396B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023138838A JP2023166470A (en) 2018-06-01 2023-08-29 Binding molecules against bcma and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862679611P 2018-06-01 2018-06-01
US62/679,611 2018-06-01
US201862684046P 2018-06-12 2018-06-12
US62/684,046 2018-06-12
PCT/IB2019/054500 WO2019229701A2 (en) 2018-06-01 2019-05-30 Binding molecules against bcma and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023138838A Division JP2023166470A (en) 2018-06-01 2023-08-29 Binding molecules against bcma and uses thereof

Publications (3)

Publication Number Publication Date
JP2021525715A JP2021525715A (en) 2021-09-27
JPWO2019229701A5 true JPWO2019229701A5 (en) 2022-06-07
JP7398396B2 JP7398396B2 (en) 2023-12-14

Family

ID=67390103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566220A Active JP7398396B2 (en) 2018-06-01 2019-05-30 Binding molecules for BCMA and their uses
JP2023138838A Pending JP2023166470A (en) 2018-06-01 2023-08-29 Binding molecules against bcma and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023138838A Pending JP2023166470A (en) 2018-06-01 2023-08-29 Binding molecules against bcma and uses thereof

Country Status (23)

Country Link
US (2) US11492409B2 (en)
EP (1) EP3802611A2 (en)
JP (2) JP7398396B2 (en)
KR (1) KR20210016390A (en)
AU (2) AU2019277029C1 (en)
BR (1) BR112020024351A2 (en)
CA (1) CA3098420A1 (en)
CL (2) CL2020003072A1 (en)
CO (1) CO2020014645A2 (en)
CR (1) CR20200571A (en)
CU (1) CU20200089A7 (en)
EC (1) ECSP20075163A (en)
IL (1) IL278959A (en)
JO (1) JOP20200307A1 (en)
MA (1) MA52785A (en)
MX (1) MX2020012495A (en)
PE (1) PE20210320A1 (en)
PH (1) PH12020552039A1 (en)
SG (1) SG11202010579XA (en)
TW (1) TW202016136A (en)
UY (1) UY38251A (en)
WO (1) WO2019229701A2 (en)
ZA (1) ZA202006474B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109641047A (en) 2016-05-20 2019-04-16 哈普恩治疗公司 Single domain seralbumin conjugated protein
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200179511A1 (en) * 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2019075378A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
EA202090817A1 (en) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. TRISSPECIFIC PROTEINS AND METHODS OF THEIR APPLICATION
MX2020013443A (en) 2018-06-13 2021-02-26 Novartis Ag Bcma chimeric antigen receptors and uses thereof.
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
KR20220024729A (en) * 2019-06-24 2022-03-03 노파르티스 아게 Dosage regimens and combination therapies for multispecific antibodies targeting B-cell maturation antigens
US20230121547A1 (en) * 2020-03-13 2023-04-20 SpringWorks Therapeutics Inc. A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof
KR20230005163A (en) 2020-03-26 2023-01-09 씨젠 인크. How to treat multiple myeloma
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
TW202208429A (en) 2020-05-11 2022-03-01 比利時商健生藥品公司 Methods for treating multiple myeloma
EP4149975A2 (en) * 2020-05-13 2023-03-22 Pfizer Inc. Methods, therapies and uses for treating cancer
CN115666723A (en) * 2020-05-21 2023-01-31 美勒斯公司 Methods and means for producing IG-like molecules
CA3180883A1 (en) * 2020-06-11 2021-12-16 Courtney BEERS Bispecific immune cell engagers with binding specificity for hla-g and another antigen
CN111848798B (en) * 2020-07-27 2022-05-13 源道隆（苏州）医学科技有限公司 Nanometer antibody capable of combining BCMA and application thereof
CN111909271B (en) * 2020-08-12 2021-03-23 深圳市茵冠生物科技有限公司 BCMA chimeric antigen receptor based on single domain antibody and application thereof
US20230193292A1 (en) * 2020-08-20 2023-06-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bcma-binding single variable structural domain and antigen-binding molecule
KR20230107663A (en) * 2020-11-19 2023-07-17 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Long-acting nerve growth factor polypeptides and uses thereof
CN116888149A (en) * 2020-12-31 2023-10-13 信达生物制药(苏州)有限公司 Heterodimeric antibody Fc-containing protein and preparation method thereof
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
CA3236930A1 (en) * 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
US20230272102A1 (en) * 2021-11-03 2023-08-31 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2023137322A1 (en) * 2022-01-11 2023-07-20 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof

Family Cites Families (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
JPS61122292A (en) 1984-11-16 1986-06-10 Teijin Ltd Production of novel carbacycline intermediate
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3777619D1 (en) 1987-01-26 1992-04-23 Ford New Holland Inc CONVEYOR DEVICE IN A BALE PRESS.
EP0276497B1 (en) 1987-01-27 1991-10-09 Agfa-Gevaert N.V. Process for the production of multiple radiographic images
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5169938A (en) * 1987-04-25 1992-12-08 Kyowa Hakko Kogyo Co., Ltd. Anti-T cell receptor γ-chain monoclonal antibody
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ATE92107T1 (en) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
JP2571874B2 (en) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド Protein microsphere composition
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
ATE221379T1 (en) 1991-05-01 2002-08-15 Jackson H M Found Military Med METHOD FOR TREATING INFECTIOUS RESPIRATORY DISEASES
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2202310T3 (en) 1991-12-13 2004-04-01 Xoma Corporation METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES.
HU215180B (en) 1992-01-23 1998-10-28 Merck Patent Gmbh. Process for production of monomeric and dimeric antibody-fragment fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK1621554T4 (en) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996040885A2 (en) 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
JP2000507912A (en) 1995-08-31 2000-06-27 アルカームズ コントロールド セラピューティックス，インコーポレイテッド Sustained release composition of active agent
EP0885002B1 (en) 1996-03-04 2011-05-11 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE69732306T2 (en) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge PREPARATION OF PARTICLE MEDICINES FOR INHALATION
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE458007T1 (en) 1998-04-20 2010-03-15 Glycart Biotechnology Ag GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODIES-DEPENDENT CELL-MEDIATED CYTOTOXICITY
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
PL393286A1 (en) 1999-01-07 2011-06-06 Zymogenetics, Inc. Soluble BR43x2 receptor and methods for the application thereof
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
CA2392477A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US20070042392A1 (en) 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2003530847A (en) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド Albumin fusion protein
WO2001087977A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
JP2004533997A (en) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Antibodies that bind both BCMA and TACI
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
ITMI20011483A1 (en) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL DEICANNABINOID RECEPTORS
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
DE10156482A1 (en) * 2001-11-12 2003-05-28 Gundram Jung Bispecific antibody molecule
MXPA04007402A (en) 2002-02-01 2005-06-17 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof.
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2484182A1 (en) * 2002-04-29 2003-11-13 Genpat77 Pharmacogenetics Ag Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
JP3975850B2 (en) 2002-07-25 2007-09-12 富士ゼロックス株式会社 Image processing device
CA2494105C (en) 2002-07-31 2013-04-02 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
ATE514713T1 (en) 2002-12-23 2011-07-15 Wyeth Llc ANTIBODIES TO PD-1 AND THEIR USE
ES2347959T3 (en) 2003-02-20 2010-11-26 Seattle Genetics, Inc. ANTI-CD70-FARMACO ANTIBODIES CONJUGATES AND THEIR USE FOR CANCER TREATMENT.
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
BRPI0410338A (en) 2003-05-31 2006-05-30 Micromet Ag pharmaceutical composition comprising a bispecific antibody construct for epcam, process for its production, use of a bispecific construct, kit containing same and method for the prevention, treatment or alleviation of a tumor disease
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP2007536898A (en) 2003-07-01 2007-12-20 セルテック アール アンド ディ リミテッド Modified antibody Fab fragment
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
EP1711470B1 (en) 2003-09-09 2009-04-15 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activtiy of gamma-secretase
SI2932981T1 (en) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
SI1673398T1 (en) 2003-10-16 2011-05-31 Micromet Ag Multispecific deimmunized cd3-binders
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
JP2007512242A (en) 2003-10-29 2007-05-17 イーラン ファーマスーティカルズ、インコーポレイテッド N-substituted benzenesulfonamide
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20070161700A1 (en) 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
EP1709072A1 (en) 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
RS50595B (en) 2004-03-23 2010-05-07 Pfizer Products Incorporated Imidazole compounds for the treatment of neurodegenerative disorders
WO2005108986A1 (en) 2004-05-10 2005-11-17 Korea Research Institute Of Bioscience And Biotechnology A diagnostic method of asthma using baff as a diagnostic marker
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP2008515780A (en) 2004-09-02 2008-05-15 ジェネンテック・インコーポレーテッド Anti-FcγRIIB receptor antibody and use thereof
MX2007002856A (en) 2004-09-02 2007-09-25 Genentech Inc Heteromultimeric molecules.
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
KR101019525B1 (en) 2004-11-12 2011-03-07 젠코어 인코포레이티드 Fc VARIANTS WITH ALTERED BINDING TO FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
BRPI0607639B1 (en) 2005-02-08 2022-04-05 Genzyme Corporation Human antibody molecules or antigen-binding fragments thereof that bind and neutralize tgf-beta1, 2 and 3, their use and pharmaceutical composition
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
JP5411430B2 (en) 2005-07-04 2014-02-12 株式会社 ニコンビジョン Ranging device
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP5686953B2 (en) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Compositions comprising cross-species-specific antibodies and uses of the compositions
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
EP3366702B1 (en) 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17 antibodies
CN102796743B (en) 2006-01-13 2015-11-18 美国政府健康及人类服务部国立卫生研究院 For codon optimized IL-15 and the IL-15R α gene of expressing in mammalian cell
RU2489423C2 (en) 2006-02-02 2013-08-10 Синтарга Б.В. Water-soluble analogues cc-1065 and their conjugates
EP1984321A1 (en) 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
JP5311303B2 (en) 2006-04-25 2013-10-09 国立大学法人 東京大学 Alzheimer's disease and cancer treatment
NZ596865A (en) 2006-06-12 2013-07-26 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
US9212230B2 (en) 2007-03-29 2015-12-15 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
ES2432792T5 (en) 2007-04-03 2023-01-16 Amgen Res Munich Gmbh Cross-species specific CD3-epsilon binding domain
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2642008T3 (en) 2007-05-11 2017-11-14 Altor Bioscience Corporation Fusion molecules and variants of IL-15
CN102131828B (en) 2007-06-18 2015-06-17 默沙东有限责任公司 Antibodies to human programmed death receptor pd-1
EP2176233A1 (en) 2007-08-07 2010-04-21 Schering Corporation Gamma secretase modulators
US8188069B2 (en) 2007-08-14 2012-05-29 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101903310B (en) 2007-10-22 2014-12-17 M技术株式会社 Process for producing organic compound
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
NZ585547A (en) 2007-11-28 2012-12-21 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
WO2009083009A2 (en) 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
CN102203132A (en) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Compositions of PD-1 antagonists and methods of use
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
EP2328934A4 (en) 2008-08-26 2013-04-03 Macrogenics Inc T-cell receptor antibodies and methods of use thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
HRP20160857T4 (en) 2008-10-01 2022-12-09 Amgen Research (Munich) Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
WO2010037838A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
KR101820535B1 (en) 2008-10-01 2018-01-19 암젠 리서치 (뮌헨) 게엠베하 Cross-species-specific psmaxcd3 bispecific single chain antibody
MX338038B (en) 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody.
US8340621B1 (en) 2008-11-19 2012-12-25 Qualcomm Incorporated Wireless device using a shared gain stage for simultaneous reception of multiple protocols
KR20210060670A (en) 2008-12-09 2021-05-26 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
LT2406284T (en) 2009-03-10 2016-10-10 Biogen Ma Inc. Anti-bcma antibodies
PT2408775E (en) 2009-03-20 2015-08-05 Sigma Tau Ind Farmaceuti Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
CA2762877A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
SI3279215T1 (en) 2009-11-24 2020-07-31 Medimmune Limited Targeted binding agents against b7-h1
LT2519543T (en) 2009-12-29 2016-10-10 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
JP5914361B2 (en) 2010-02-05 2016-05-11 ヘプタレス セラピューティックス リミテッド 1,2,4-Triazine-4-amine-containing derivatives
CN102892786B (en) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1 antibody
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
ES2365960B1 (en) 2010-03-31 2012-06-04 Palobiofarma, S.L NEW ANTAGONISTS OF ADENOSINE RECEPTORS.
KR101747991B1 (en) 2010-04-13 2017-06-19 메디뮨 엘엘씨 Trail r2-specific multimeric scaffolds
CN110066339A (en) 2010-04-20 2019-07-30 根马布股份公司 Albumen of the FC containing heterodimeric antibodies and preparation method thereof
CA2814155C (en) 2010-06-11 2019-10-22 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
EP2448371A1 (en) 2010-10-26 2012-05-02 Belux IP AG Method and switching assembly for operating an LED module for lighting purposes
ES2758994T3 (en) 2010-11-05 2020-05-07 Zymeworks Inc Stable heterodimeric antibody design with mutations in the Fc domain
DK2649086T3 (en) 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
US20120213768A1 (en) 2011-02-19 2012-08-23 Baylor Research Institute Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
TWI530489B (en) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
KR101970025B1 (en) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Antibodies and other molecules that bind b7-h1 and pd-1
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
BR112013028779B8 (en) 2011-05-27 2021-04-20 Glaxo Group Ltd antigen-binding protein or immunoconjugate, immunoconjugate, pharmaceutical composition, and, use of a composition
UA112434C2 (en) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед ANTIGENCY BINDING SPECIFICALLY Binds to ALL
ES2894398T3 (en) 2011-06-03 2022-02-14 Xoma Technology Ltd Specific antibodies to TGF-beta
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
ES2664622T3 (en) 2011-07-24 2018-04-20 Cure Tech Ltd. Humanized immunomodulatory monoclonal antibody variants
WO2013036464A1 (en) 2011-09-09 2013-03-14 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
PL2771364T3 (en) 2011-10-27 2020-01-31 Genmab A/S Production of heterodimeric proteins
WO2013066740A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Gamma secretase modulators
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013085925A1 (en) 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
WO2013096901A1 (en) 2011-12-23 2013-06-27 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
RU2650805C2 (en) 2012-04-11 2018-04-17 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Chimeric antigen receptors targeting b-cell maturation antigen
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
KR20220084444A (en) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Antigen binding proteins that bind pd-l1
MX2014014894A (en) 2012-06-04 2015-02-20 Irm Llc Site-specific labeling methods and molecules produced thereby.
JO3300B1 (en) 2012-06-06 2018-09-16 Novartis Ag Compounds and compositions for modulating egfr activity
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
CN111499755A (en) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 anti-PD-L1 and PD-L2 double-binding antibody single reagents and methods of use thereof
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AU2013334610B2 (en) 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
US10189906B2 (en) 2012-11-01 2019-01-29 Max-Delrück-Centrum Für Molekulare Medizin Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
KR102264570B1 (en) 2012-11-28 2021-06-14 자임워크스 인코포레이티드 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9464103B2 (en) 2012-11-29 2016-10-11 Merck Sharp & Dohme Corp. Spirocyclic sulfones as gamma secretase inhibitors
TW201425336A (en) * 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
WO2014110601A1 (en) * 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
JP2016507066A (en) 2013-02-08 2016-03-07 インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-Hodgkin lymphoma
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
US9193788B2 (en) 2013-02-08 2015-11-24 Novartis Ag Anti-IL-17A antibodies and their uses
SG10201706468RA (en) 2013-02-08 2017-09-28 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
TWI658051B (en) 2013-03-15 2019-05-01 葛蘭素史密斯克藍智慧財產發展有限公司 Antigen binding proteins
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014150973A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
EP3770176A1 (en) 2013-05-02 2021-01-27 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
CN111423511B (en) 2013-05-31 2024-02-23 索伦托药业有限公司 Antigen binding proteins that bind to PD-1
TWI725931B (en) 2013-06-24 2021-05-01 美商建南德克公司 Anti-fcrh5 antibodies
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
FR3008408B1 (en) 2013-07-11 2018-03-09 Mc Saf NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY
KR102236367B1 (en) 2013-07-26 2021-04-05 삼성전자주식회사 Bispecific chimeric proteins with DARPins
PL3702373T3 (en) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
HRP20220214T1 (en) 2014-01-15 2022-04-29 Kadmon Corporation, Llc Immunomodulatory agents
US20170015758A1 (en) 2014-01-21 2017-01-19 Medimmune, Llc Compositions And Methods For Modulating And Redirecting Immune Responses
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JP2017505773A (en) 2014-01-28 2017-02-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-LAG-3 antibody for treating hematological malignancies
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
BR112016020065A2 (en) 2014-03-12 2018-02-20 Novartis Ag specific sites to modify antibodies to make immunoconjugates
ES2770684T3 (en) 2014-03-14 2020-07-02 Novartis Ag LAG-3 Antibody Molecules and Uses thereof
KR102632731B1 (en) 2014-04-30 2024-02-01 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Humanized antibodies against cd269(bcma)
JP6666905B2 (en) 2014-05-29 2020-03-18 スプリング バイオサイエンス コーポレーション PD-L1 antibody and use thereof
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
TWI726608B (en) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
RU2751660C2 (en) 2014-07-21 2021-07-15 Новартис Аг Treatment of malignant neoplasm using humanized chimeric antigen receptor against bcma
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
RU2700027C2 (en) 2014-08-05 2019-09-12 Басф Се Diphosphite derivatives 3-phenylbenzofuran-2-one as stabilizers
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
US10766966B2 (en) 2014-10-10 2020-09-08 Innate Pharma CD73 blockade
PE20171067A1 (en) 2014-10-14 2017-07-24 Novartis Ag ANTIBODY MOLECULES BINDING AND USES OF PD-L1
MX2017005920A (en) 2014-11-06 2017-06-27 Hoffmann La Roche Anti-tim3 antibodies and methods of use.
MY191423A (en) 2014-11-10 2022-06-27 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
US20160129108A1 (en) 2014-11-11 2016-05-12 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
SI3221363T1 (en) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
TN2017000222A1 (en) * 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
WO2016086186A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
JP6696982B2 (en) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Heterodimeric antibodies that bind to CD3 and tumor antigens
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CA2974434A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
SG11201704548PA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
RS62527B1 (en) 2014-12-12 2021-11-30 2Seventy Bio Inc Bcma chimeric antigen receptors
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016130598A1 (en) 2015-02-09 2016-08-18 University Of Florida Research Foundation, Inc. Bi-specific chimeric antigen receptor and uses thereof
CN111067623A (en) 2015-03-05 2020-04-28 思想外科有限公司 Method for locating and tracking tool axis
CA2978892A1 (en) 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
US10428149B2 (en) 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
MA41867A (en) 2015-04-01 2018-02-06 Anaptysbio Inc T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3)
SI3280729T1 (en) 2015-04-08 2022-09-30 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
US9969809B2 (en) 2015-04-13 2018-05-15 Pfizer Inc. Therapeutic antibodies and their uses
KR102528825B1 (en) 2015-04-13 2023-05-08 화이자 인코포레이티드 Chimeric antigen receptors targeting b-cell maturation antigen
CN115536750A (en) 2015-05-08 2022-12-30 森科股份有限公司 Heterodimeric antibodies binding to CD3 and tumor antigens
KR20180023952A (en) 2015-06-16 2018-03-07 제넨테크, 인크. Humanized and Affinity Maturation Antibodies to FcRH5 and Methods of Use
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
KR20180033232A (en) 2015-07-24 2018-04-02 온코트랙커 인코포레이티드 Gamma secretase modulator for the treatment of immune system dysfunction
HUE048939T2 (en) 2015-08-03 2020-09-28 Engmab Sarl Monoclonal antibodies against human b cell maturation antigen (bcma)
CN108348521B (en) 2015-08-11 2021-12-03 诺华股份有限公司 5-bromo-2, 6-di- (1H-pyrazol-1-yl) pyrimidin-4-amines for the treatment of cancer
PE20180795A1 (en) 2015-08-17 2018-05-09 Janssen Pharmaceutica Nv ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND THE USE OF THEM
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
JP7267009B2 (en) 2015-12-04 2023-05-01 メモリアル スローン ケタリング キャンサー センター Antibodies targeting Fc receptor-like 5 and methods of use
TW201731872A (en) 2015-12-18 2017-09-16 諾華公司 Antibodies targeting CD32b and methods of use thereof
MA43874A (en) 2016-01-13 2018-11-21 Compass Therapeutics Llc MULTISPECIFIC IMMUNOMODULATOR ANTIGEN BINDING CONSTRUCTIONS
TWI797073B (en) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 Pharmaceutical composition comprising bispecific antibody constructs
UA126657C2 (en) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг Bcma and cd3 bispecific t cell engaging antibody constructs
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
MX2018015592A (en) * 2016-06-14 2019-04-24 Xencor Inc Bispecific checkpoint inhibitor antibodies.
KR20190053835A (en) 2016-06-21 2019-05-20 테네오바이오, 인코포레이티드 CD3 binding antibody
WO2018083204A1 (en) 2016-11-02 2018-05-11 Engmab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
CN110431151B (en) 2016-12-21 2023-07-18 特尼奥生物股份有限公司 Heavy chain-only anti-BCMA antibodies
WO2018133877A1 (en) 2017-01-23 2018-07-26 科济生物医药（上海）有限公司 Bcma-targeting antibody and use thereof
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JP7325936B2 (en) 2017-05-05 2023-08-15 アムジエン・インコーポレーテツド Pharmaceutical compositions comprising bispecific antibody constructs for improved storage and administration
EP3642237A2 (en) 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
EP3642236A1 (en) 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Chimeric antibody immune effctor cell engagers and methods of use thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
WO2019075378A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
EA202090817A1 (en) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. TRISSPECIFIC PROTEINS AND METHODS OF THEIR APPLICATION
US20210189336A1 (en) 2017-10-18 2021-06-24 Vivia Biotech, S.L. Bite-activated car-t cells
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen

Similar Documents

Publication Publication Date Title
JPWO2019229701A5 (en)
JP2020504723A5 (en)
JP2021501162A5 (en)
RU2008149918A (en) ANTIBODIES TO NKG2A AND THEIR APPLICATION
RU2017121327A (en) COMBINED THERAPY BASED ON ACTIVATING T-CELLS OF SPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND T-LINK-BINDER
RU2012119788A (en) BINDING IL-1 PROTEINS
JP2012530496A5 (en)
JP2009536921A5 (en)
JPWO2019129221A5 (en)
JP2016505546A5 (en)
JPWO2019033043A5 (en)
IL305954A (en) Anti-nectin-4 antibody exatecan conjugates
JP2022521305A (en) Anti-PD-L1 antibody and its use
JP2023504530A (en) Compositions of TriAx Antibodies, Methods of Making and Using the Same
JP2023532129A (en) Multispecific antibodies that bind to BCMA
WO2022221698A1 (en) Anti-cd20 antibodies and car-t structures
IL302670A (en) Heavy chain antibodies binding to folate receptor alpha
WO2023174405A1 (en) Claudin18.2 humanized antibody and application thereof
RU2020143237A (en) BCMA BINDING MOLECULES AND THEIR APPLICATIONS
JPWO2020011964A5 (en)
JPWO2019137541A5 (en)
US20230312742A1 (en) CD38 antibodies for the treatment of human diseases
JPWO2021011885A5 (en)
JPWO2019165421A5 (en)
IL298024A (en) Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof